DeepMed Research

Cilostazol

Generic Name: Cilostazol

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₇N_₅O_₂

CAS Number: 73963-72-1

Unique Ingredient Identifier: N7Z035406B

Background: Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

Indication: Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions: Intermittent Claudication

Clinical Trials

CiLostAzol for pReventIon of Recurrent sTroke in Africa

Phase 3

Not yet recruiting

Conditions: Stroke

Interventions: Drug: Cilostazol 100 mg

First Posted Date: 2025-04-09

Last Posted Date: 2025-05-04

Lead Sponsor: Northern California Institute of Research and Education

Target Recruit Count: 1100

Registration Number: NCT06919835

Locations: 🇬🇭
Kwame Nkrumah University of Science & Technology, Kumasi, Ghana

Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication

Phase 3

Terminated

Conditions: Intermittent Claudication

Interventions: Drug: Cilostazol 200 mg
Drug: Cilostazol 100 mg

First Posted Date: 2025-03-20

Last Posted Date: 2025-03-20

Lead Sponsor: Genovate Biotechnology Co., Ltd.,

Target Recruit Count: 14

Registration Number: NCT06886620

Locations: 🇨🇳
Cheng Hsin General Hospital, Taipei, Taiwan
🇨🇳
Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

and more 2 locations

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Phase 4

Not yet recruiting

Conditions: Cerebral Infarction
Stenosis Artery

Interventions: Drug: Aspirin
Drug: Clopidogrel
Drug: Cilostazol
Drug: Placebo

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-06

Lead Sponsor: Asan Medical Center

Target Recruit Count: 2340

Registration Number: NCT06757764

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Recruiting

Conditions: Stroke, Ischemic
Small Vessel Cerebrovascular Disease
White Matter Hyperintensity

Interventions: Drug: Clopidogrel
Drug: Aspirin
Drug: Cilostazol + Isosorbide Mononitrate

First Posted Date: 2024-12-04

Last Posted Date: 2025-03-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 300

Registration Number: NCT06715007

Locations: 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Cilostazol in Parkinson's Disease

Phase 2

Not yet recruiting

Conditions: Parkinson's Disease

Interventions: Drug: Cilostazol
Drug: Placebo
Drug: Standard treatment

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 50

Registration Number: NCT06612593

Locations: 🇪🇬
Ain Shams University Hospital, Cairo, Egypt

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Cilostazol 100 MG
Drug: Aspirin 75mg

First Posted Date: 2024-09-19

Last Posted Date: 2025-01-13

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06591377

Locations: 🇪🇬
El-sahel teaching hospital, Cairo, Egypt
🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Cilostazol 100 MG
Drug: Clopidogrel 75mg

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 870

Registration Number: NCT06591299

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Cilostazol 100 MG
Drug: Clopidogrel

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 870

Registration Number: NCT06591351

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Ticagrelor 90 MG
Drug: Cilostazol 100 MG

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06591390

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Ticagrelor Versus Cilostazol in Ischemic Stroke

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Cilostazol 100 MG
Drug: Ticagrelor 90 MG

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-20

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 900

Registration Number: NCT06561867

Locations: 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy